Aspen set to sign deal with Indian maker of API

Aspen is delivering on its plan to deleverage its balance sheet, cut debt and improve its cash conversion ratio which came to fruition in the second half of the year. With all those factors coming together, the one aspect that doesn't seem to be coming through for the pharmaceutical group is revenue growth, up a tepid 1% over the annual period. Business Day TV's Giulietta caught up with the company's Group Chief Executive, Stephen Saad and asked him how he plans to resuscitate growth on that front.
Loading player...